Pharmacology Unit, School of Pharmacy, University of Camerino, Via Madonna delle Carceri, Camerino, Italy.
Addict Biol. 2013 Jul;18(4):644-53. doi: 10.1111/j.1369-1600.2012.00468.x. Epub 2012 Jun 27.
Pregabalin (Lyrica™) is a structural analog of γ-aminobutyric acid (GABA) and is approved by the FDA for partial epilepsy, neuropathic pain and generalized anxiety disorders. Pregabalin also reduces excitatory neurotransmitter release and post-synaptic excitability. Recently, we demonstrated that pregabalin reduced alcohol intake and prevented relapse to the alcohol seeking elicited by stress or environmental stimuli associated with alcohol availability. Here, we sought to extend these findings by examining the effect of pregabalin on cocaine self-administration (0.25 mg/infusion) and on cocaine seeking elicited by both conditioned stimuli and stress, as generated by administration of yohimbine (1.25 mg/kg). The results showed that oral administration of pregabalin (0, 10 or 30 mg/kg) reduced self-administration of cocaine over an extended period (6 hours), whereas it did not modify self-administration of food. In cocaine reinstatement studies, pregabalin (10 and 30 mg/kg) abolished the cocaine seeking elicited by both the pharmacological stressor yohimbine and the cues predictive of cocaine availability. Overall, these results demonstrate that pregabalin may have potential in the treatment of some aspects of cocaine addiction.
普瑞巴林（Lyrica™）是γ-氨基丁酸（GABA）的结构类似物，已被 FDA 批准用于治疗部分癫痫、神经病理性疼痛和广泛性焦虑症。普瑞巴林还能减少兴奋性神经递质的释放和突触后兴奋性。最近，我们证明普瑞巴林可减少酒精摄入量，并防止因压力或与酒精供应相关的环境刺激引起的酒精寻求复发。在这里，我们试图通过检查普瑞巴林对可卡因自我给药（0.25 毫克/输注）的影响以及对条件刺激和应激引起的可卡因寻求的影响来扩展这些发现，这是通过给予育亨宾（1.25 毫克/千克）来实现的。结果表明，普瑞巴林（0、10 或 30 毫克/千克）口服给药可在较长时间内（6 小时）减少可卡因的自我给药，而不会改变食物的自我给药。在可卡因复吸研究中，普瑞巴林（10 和 30 毫克/千克）消除了育亨宾和预测可卡因可用性的线索引起的可卡因寻求。总的来说，这些结果表明普瑞巴林可能在治疗可卡因成瘾的某些方面具有潜力。
